文献速递免疫规划传染病防控与疫情报告

尼日尔2010-2018年引入13价肺炎球菌结合疫苗前后肺炎球菌脑膜炎特征分析

Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010-2018.
PubMed 文献 · Vaccine · 2020-04-21

该研究利用尼日尔国家脑膜炎参考实验室2010-2018年脑脊液监测数据,对检测出的肺炎球菌进行血清分型,比较引入PCV13前(2010-2012年)与后(2016-2018年)的血清型分布。结果显示,PCV13相关血清型占比在<5岁儿童中从74.0%降至28.1%(P<0.05),但≥5岁人群中仍超过50%,血清型1仍是该人群主要致病血清型。

要点

  • 尼日尔2014年引入PCV13,接种程序为6、10、14周龄各一剂。
  • 引入PCV13后,<5岁儿童中疫苗相关血清型占比从74.0%降至28.1%(P<0.05)。
  • ≥5岁人群中疫苗相关血清型仍占肺炎球菌脑膜炎的50%以上,血清型1最常见。

核心结论

  • 引入PCV13后,尼日尔疫苗相关血清型引起的肺炎球菌脑膜炎报告病例比例下降;但血清型1仍是较大儿童和成人肺炎球菌脑膜炎的主要病因。
  • 作者认为,除加强监测外,还需采取不同的疫苗接种策略,如改变婴儿接种程序或将疫苗覆盖扩展至较大儿童和成人。

研究设计与样本

  • 利用尼日尔国家脑膜炎参考实验室(CERMES)2010年1月至2018年12月收到的疑似细菌性脑膜炎脑脊液标本监测数据。
  • CERMES共收到16,155份标本,其中5,651份(35%)经培养或聚合酶链反应(PCR)确认细菌学病因。
  • 肺炎链球菌占5,651份中的13.2%(744/5,651),其中53.1%(395/744)完成血清分型。
  • 对2010-2018年检出肺炎链球菌的标本送至美国疾病控制与预防中心,采用序贯三重实时PCR进行血清分型;实时PCR无法分型的标本采用常规多重PCR分型。
  • 比较引入PCV13前(2010-2012年)与后(2016-2018年)肺炎球菌血清型分布的差异。

主要发现

  • 2010-2012年,PCV13相关血清型(VT)占已分型肺炎球菌阳性标本的四分之三。
  • 2016-2018年,VT比例在所有年龄组均下降,<5岁儿童下降最明显,从74.0%降至28.1%(P<0.05)。
  • ≥5岁人群中,引入PCV13后VT仍占肺炎球菌脑膜炎的50%以上。
  • 血清型1在≥5岁人群中仍是最常见的VT,但在<5岁人群中不是。

临床怎么用

  • 作者认为,除加强监测外,还需采取不同的疫苗接种策略,如改变婴儿接种程序或将疫苗覆盖扩展至较大儿童和成人。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pneumococcal meningitis in the African meningitis belt is primarily caused by Streptococcus pneumoniae serotype 1, a serotype contained in the 13-valent pneumococcal conjugate vaccine (PCV13). In 2014, Niger introduced PCV13 with doses given at 6, 10, and 14 weeks of age. We leveraged existing meningitis surveillance data to describe pneumococcal meningitis trends in Niger. As a national reference laboratory for meningitis, Centre de Recherche Médicale et Sanitaire (CERMES) receives cerebrospinal fluid specimens from suspected bacterial meningitis cases and performs confirmatory testing for an etiology by culture or polymerase chain reaction (PCR). Specimens with S. pneumoniae detection during 2010-2018 were sent to the Centers for Disease Control and Prevention for serotyping by sequential triplex real-time PCR. Specimens that were non-typeable by real-time PCR underwent serotyping by conventional multiplex PCR. We tested differences in the distribution of pneumococcal serotypes before (2010-2012) and after (2016-2018) PCV13 introduction. During January 2010 to December 2018, CERMES received 16,155 specimens; 5,651 (35%) had bacterial etiology confirmed. S. pneumoniae accounted for 13.2% (744/5,651); 53.1% (395/744) were serotyped. During 2010-12, PCV13-associated serotypes (VT) constituted three-fourths of serotyped pneumococcus-positive specimens; this proportion declined in all age groups in 2016-18, most substantially in children aged < 5 years (74.0% to 28.1%; P < 0.05). Among persons aged ≥ 5 years, VT constituted > 50% of pneumococcal meningitis after PCV13 introduction; serotype 1 remained the most common VT among persons aged ≥ 5 years, but not among those < 5 years. VT as a group caused a smaller proportion of reported pneumococcal meningitis cases after PCV13 introduction in Niger. Serotype 1, however, remains the major cause of pneumococcal meningitis in older children and adults. Different vaccination strategies, such as changing the infant vaccination schedule or extending vaccine coverage to older children and adults, are needed, in addition to stronger surveillance.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ousmane S, Kobayashi M, Seidou I, et al. Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010-2018. Vaccine. 2020. PMID: 32327220. doi:10.1016/j.vaccine.2020.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。